Evaluation of harm reduction programs on seroincidence of hiv, hepatitis b and c, and syphilis among intravenous drug users in Southwest China

Sexually Transmitted Diseases

Volumn 40, Issue 4, 2013, Pages 323-328

  Ruan, Yuhua ^a   Liang, Shu ^b   Zhu, Junling ^a   Li, Xudong ^a,c   Pan, Stephen W ^d   Liu, Qianping ^e   Song, Benli ^e   Wang, Qixing ^f   Xing, Hui ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Sichuan Provincial Center for Disease Control and Prevention   (China)

^c TIANJIN CENTERS FOR DISEASE CONTROL AND PREVENTION   (China)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Xichang Center for STD and Leprosy Control   (China)

^f Liangshan Prefecture Center for Disease Control and Prevention Xichang   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; METHADONE; VIRUS ANTIBODY;

ADULT; ARTICLE; CHINA; COHORT ANALYSIS; CONDOM; DRUG TRAFFIC; FEMALE; FOLLOW UP; HARM REDUCTION; HEPATITIS B; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PROSPECTIVE STUDY; SEROCONVERSION; SYPHILIS;

ADULT; CHINA; COHORT STUDIES; FEMALE; HARM REDUCTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NEEDLE-EXCHANGE PROGRAMS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SYPHILIS;

EID: 84875154615     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31827fd4d4     Document Type: Article

References (27)

1. Zhang KL, Ma SJ. Epidemiology of HIV in China. BMJ 2002; 324: 803-804.
2. UNAIDS Task Force on Drug Use and HIV. Drug Use and HIV Vulnerability: Policy Research Study in Asia. Bangkok: UNAIDS Asia Pacific Intercountry Team, 2000.
3. Security, C.M.O.P. Registered number of drug users in China updated through June of 2009. 2009. Available at: http://www.mps.gov. cn/n16/n1252/n1897/n2872/2077880.html. Beijing, China. Accessed October 23, 2009.
4. China NNCC. Annual Report on Drug Control in china. Beijing, China: National Narcotics Control Commission, 2002.
5. Qian HZ, Vermund SH, Wang N. Risk of HIV/AIDS in China: Subpopulations of special importance. Sex Transm Infect 2005; 81: 442-447.
6. Qian HZ, Schumacher JE, Chen HT, et al. Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications. Harm Reduct J 2006; 3: 4.
7. Ma Y, Li ZZ, Zhao SD. HIV was first discovered among IDUs in China. Zhonghua Liu Xing Bing Xue Za Zhi 1990; 11: 184-185.
8. China CDC. Analysis of HIV/STD Epidemic in 2002. Beijing, China: China Center for Disease Control and Prevention, 2002.
9. China CDC. Analysis of HIV/STD Epidemic in 2004. Beijing, China: China Center for Disease Control and Prevention, 2004.
10. Ruan Y, Qin G, Liu S, et al. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr 2005; 39: 459-463.
11. Zhang Y, Shan H, Trizzino J, et al. HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis 2007; 11: 318-323.
12. Wei L, Chen J, Rodolph M, et al. HIV incidence, retention, and changes of high-risk behaviors among rural injection drug users in Guangxi, China. Subst Abuse 2006; 27: 53-61.
13. Yin L, Qin G, Qian HZ, et al. Continued spread of HIV among injecting drug users in southern Sichuan Province, China. Harm Reduct J 2007; 4: 6.
14. The Ministry of Health of the People's Republic of China, Joint United Nations Programme on HIV/AIDS and World Health Organization: 2005 Update on the HIV/AIDS Epidemic and Response in China; January 24, 2006.
15. Han MG, Chen QF, Han Y, et al. Design and implementation of a China comprehensive AIDS response programme (China CARES), 2003-08. Int J Epidemiol 2010; 39: ii47Yii55.
16. Liu B, Sullivan SG, Wu Z. An evaluation of needle exchange programmes in China. AIDS 2007; 21(suppl 8): S123YS128.
17. Yin WZ, Hao Y, Sun XH, et al. Scaling up the national methadone maintenance treatment program in China: Achievements and challenges. Int J Epidemiol 2010; 39: ii29Yii37.
18. Rou KM, Sullivan SG, Liu P, et al. Scaling up prevention programmes to reduce the sexual transmission of HIV in China. Int J Epidemiol 2010; 39: ii38Yii46.
19. China CDC. Analysis of HIV/STD Epidemic in 2011. Beijing, China: China Center for Disease Control and Prevention, 2011.
20. Qian HZ, Hao C, Ruan Y, et al. Impact of methadone on drug use and risky sex in China. J Subst Abuse Treat 2008; 34: 391-397.
21. Bao YP, Liu ZM, Lu L. Reviewof HIVand HCV infection among drug users in China. Curr Opin Psychiatry 2010; 23: 187-194. [Epub ahead of print].
22. Xia X, Luo J, Bai J, et al. Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis. Public Health 2008; 122: 990-1003.
23. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: How much really is known? Sex Transm Dis 2001; 28: 579-597.
24. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19: 61-77.
25. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
26. Hao C, Wu JL, Ruan YH, et al. Factors associated with retention in a community-based methadone maintenance treatment among heroin addicts. Chin J Prev Med 2007; 41: 250-253.
27. Wang J, Li F, Mo LR, et al. Factors associated with retention in a community-based methadone maintenance treatment among drug users in Urumqi, Xinjiang Uigur Autonomous Region. Chin J Epidemiol 2007; 28: 37-41.